AU2019300782B2 - Generating CIK NKT cells from cord blood - Google Patents

Generating CIK NKT cells from cord blood Download PDF

Info

Publication number
AU2019300782B2
AU2019300782B2 AU2019300782A AU2019300782A AU2019300782B2 AU 2019300782 B2 AU2019300782 B2 AU 2019300782B2 AU 2019300782 A AU2019300782 A AU 2019300782A AU 2019300782 A AU2019300782 A AU 2019300782A AU 2019300782 B2 AU2019300782 B2 AU 2019300782B2
Authority
AU
Australia
Prior art keywords
cells
nkt cells
cik nkt
cik
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019300782A
Other languages
English (en)
Other versions
AU2019300782A1 (en
Inventor
Rohit Duggal
Ranjeet SINHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
Immunitybio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunitybio Inc filed Critical Immunitybio Inc
Publication of AU2019300782A1 publication Critical patent/AU2019300782A1/en
Assigned to IMMUNITYBIO, INC. reassignment IMMUNITYBIO, INC. Amend patent request/document other than specification (104) Assignors: NANTKWEST, INC.
Application granted granted Critical
Publication of AU2019300782B2 publication Critical patent/AU2019300782B2/en
Priority to AU2024200673A priority Critical patent/AU2024200673B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
AU2019300782A 2018-07-10 2019-07-01 Generating CIK NKT cells from cord blood Active AU2019300782B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024200673A AU2024200673B2 (en) 2018-07-10 2024-02-03 Generating CIK NKT cells from cord blood

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696131P 2018-07-10 2018-07-10
US62/696,131 2018-07-10
PCT/US2019/040145 WO2020014029A1 (en) 2018-07-10 2019-07-01 Generating cik nkt cells from cord blood

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200673A Division AU2024200673B2 (en) 2018-07-10 2024-02-03 Generating CIK NKT cells from cord blood

Publications (2)

Publication Number Publication Date
AU2019300782A1 AU2019300782A1 (en) 2021-01-14
AU2019300782B2 true AU2019300782B2 (en) 2023-12-21

Family

ID=67551410

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019300782A Active AU2019300782B2 (en) 2018-07-10 2019-07-01 Generating CIK NKT cells from cord blood
AU2024200673A Active AU2024200673B2 (en) 2018-07-10 2024-02-03 Generating CIK NKT cells from cord blood

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024200673A Active AU2024200673B2 (en) 2018-07-10 2024-02-03 Generating CIK NKT cells from cord blood

Country Status (9)

Country Link
US (2) US11931382B2 (https=)
EP (1) EP3820994A1 (https=)
JP (3) JP7190022B2 (https=)
KR (3) KR102721222B1 (https=)
CN (2) CN119372142A (https=)
AU (2) AU2019300782B2 (https=)
CA (1) CA3105601C (https=)
IL (2) IL319500A (https=)
WO (1) WO2020014029A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114925B1 (en) * 2020-03-04 2025-11-05 Bioeclipse Therapeutics, Inc. Methods of manufacturing activated immune cells
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
CN111690607B (zh) * 2020-06-19 2022-02-18 珠海贝索细胞科学技术有限公司 一种高效杀伤细胞体外培养试剂盒及培养方法
CN112251407A (zh) * 2020-11-03 2021-01-22 广州康琪莱精准医疗科技有限公司 一种脐带血cik细胞的扩增培养方法
CN114807044B (zh) * 2021-04-30 2023-09-08 四川大学华西医院 一种具有高nkt细胞比例的car-cik细胞制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170042939A1 (en) * 2015-08-13 2017-02-16 Tsinghua University Nkt-like cell subpopulation and method of using the same in the treatment of tumor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
TR200001253T2 (tr) 1997-11-06 2000-11-21 Roche Diagnostics Gmbh Tümöre özel antijenler
WO2000020460A1 (en) 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
US7098008B2 (en) 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
EP1288291A4 (en) * 2000-06-06 2004-05-12 Kirin Brewery METHOD FOR REPLACING NATURAL KILLER T CELLS
EP1653977A2 (en) * 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of disorders associated with natural killer t cells
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
CN102575231B (zh) 2009-10-28 2013-09-11 宝生物工程株式会社 制备细胞因子诱导的杀伤细胞的方法
US20130059379A1 (en) * 2010-02-24 2013-03-07 Ingo Schmidt-Wolf Method for the generation of a cik cell and nk cell population
US20130189268A1 (en) 2010-06-22 2013-07-25 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies
ES2602743T3 (es) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
WO2013051718A1 (ja) 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
ES2654060T3 (es) 2011-10-20 2018-02-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Receptores de antígenos quiméricos anti-CD22
JP2015526088A (ja) 2012-08-13 2015-09-10 アントフロゲネシス コーポレーション ナチュラルキラー細胞及びその使用
MX367730B (es) 2012-09-04 2019-09-04 Cellectis Receptor de antigeno quimerico multi-cadena y usos del mismo.
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
WO2015112793A2 (en) * 2014-01-27 2015-07-30 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
CN104017770B (zh) 2014-06-23 2015-04-29 山东赛乐中德生物科技有限公司 一种利用糖脂制备cik细胞的方法
TWI702290B (zh) * 2015-04-07 2020-08-21 富禾生醫股份有限公司 經修飾之自然殺手ｔ細胞、醫藥組合物及其用途
CN105176927B (zh) * 2015-10-15 2019-01-18 丛秀丽 一种细胞毒性增强的高效靶向杀伤nk/cik细胞的制备方法
CN106566807A (zh) * 2016-10-21 2017-04-19 闾军 一种浓度梯度rhIL‑2依赖的iNKT细胞扩增方法及其应用
CN106434556B (zh) * 2016-11-22 2019-10-11 上海新长安生物科技有限公司 一种体外诱导扩增i型nkt细胞的方法
EP3634437A4 (en) * 2017-05-19 2020-11-18 Case Western Reserve University COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
EP4017509A4 (en) * 2019-08-21 2023-09-13 Akeso Therapeutics, Inc. TYPE III NKT CELLS AND RELATED COMPOSITIONS AND METHODS
CN111172110B (zh) * 2019-12-20 2022-04-22 中科细胞科技(广州)有限公司 一种脐带血cik细胞的培养方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170042939A1 (en) * 2015-08-13 2017-02-16 Tsinghua University Nkt-like cell subpopulation and method of using the same in the treatment of tumor

Also Published As

Publication number Publication date
IL279924A (en) 2021-03-01
CN119372142A (zh) 2025-01-28
JP2021530224A (ja) 2021-11-11
CA3105601C (en) 2024-01-16
AU2024200673A1 (en) 2024-03-07
CN112424343A (zh) 2021-02-26
KR102577954B1 (ko) 2023-09-14
KR20210028675A (ko) 2021-03-12
JP2025015816A (ja) 2025-01-30
KR20240154707A (ko) 2024-10-25
AU2019300782A1 (en) 2021-01-14
IL279924B2 (en) 2025-08-01
CA3105601A1 (en) 2020-01-16
JP2023012503A (ja) 2023-01-25
US11931382B2 (en) 2024-03-19
WO2020014029A1 (en) 2020-01-16
IL319500A (en) 2025-05-01
AU2024200673B2 (en) 2026-02-05
JP7190022B2 (ja) 2022-12-14
KR20230133942A (ko) 2023-09-19
KR102778139B1 (ko) 2025-03-10
US20240180967A1 (en) 2024-06-06
KR102721222B1 (ko) 2024-10-24
JP7664207B2 (ja) 2025-04-17
EP3820994A1 (en) 2021-05-19
IL279924B1 (en) 2025-04-01
CN112424343B (zh) 2024-10-22
US20220347218A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
AU2024200673B2 (en) Generating CIK NKT cells from cord blood
Motohashi et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non–small cell lung cancer
DE102018108612A1 (de) Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
KR101299299B1 (ko) 암면역 요법용 세포의 제조방법
US11351196B2 (en) Generating CIK NKT cells from cord blood
JP2021516666A (ja) 前立腺がん特異的髄浸潤リンパ球およびその使用
Faeq et al. CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies
Asl et al. Intra-lesion injection of activated Natural Killer (NK) cells in recurrent malignant brain tumors
AU2026202465A1 (en) Generating CIK NKT cells from cord blood
US20200306302A1 (en) Treating and inhibiting leukemia with nk-92 cells
US20260027155A1 (en) Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products
HK40120022A (zh) 从脐带血产生cik nkt细胞
US20240335472A1 (en) Anti-her2 car nk cells, methods of their production and uses thereof
HK40018395A (en) Treating and inhibiting leukemia with nk-92 cells
Guthrie et al. CAR-T CELL THERAPY: A REVOLUTIONARY CANCER TREATMENT

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: IMMUNITYBIO, INC.

Free format text: FORMER NAME(S): NANTKWEST, INC.

FGA Letters patent sealed or granted (standard patent)